Medical device maker Dexcom said it has received a warning letter from the U.S. Food and Drug Administration following ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz.

BofA keeps a Buy rating on DexCom (DXCM) with a $105 price target after Dexcom announced it received a warning letter from the FDA. Importantly, ...

DexCom (DXCM) does not expect a material impact from the FDA’s warning letter to its manufacturing capacity or its fiscal year 2025 guidance ...

In a regulatory filing, DexCom (DXCM) disclosed that on March 4, the company received a warning letter from the U.S. FDA following inspections ...

Dexcom (NASDAQ: DXCM) received a warning letter from the U.S. Food and Drug Administration (FDA) after inspections at its key ...

Dexcom (Nadsaq:DXCM) announced today that it received a warning letter from the FDA following inspections of two company ...

The latest health news includes Johnson & Johnson halting testing on a depression drug, USDA eliminating food safety advisory ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...

Tandem Diabetes Care announced that the FDA cleared its Control-IQ+ automated insulin delivery algorithm for people with type ...

(Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation ...